Accepted at 1:06 a.m. Nov, 19, 2025 by andrewmathias8
Author: lawsonspence
Co-authors: mitchelnelson
Related Note: 1488768082952 1
Rationale for change

list from AMBOSS

putting them here helps to continuously associate the drug names with their MOA

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Empty field
Additional Resources
One by one
Empty field
#AK_Step2_v12::#AMBOSS::7C04tR #AK_Step2_v12::#UWorld::Step::4649 #AK_Step2_v12::#UWorld::#UWSA1 #PANCE::EOR::IM #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::02_DirectThrombinInhibitors_DirectFactorXaInhibitors #AK_Step2_v12::#B&B::02_Cardio::01_Arrhythmias::03_Atrial_Fibrillation_and_Flutter #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::01_Heparin,_LMWH,_fondaparinux,_direct_thrombin_inhibitors,_Xa_inhibitors #AK_Step2_v12::#SketchyIM::02_ECG_Interpretation_&_Arrhythmias::05_Retired_Lessons::04_Tachycardia::02_Narrow_Complex_Tachycardia_AFib_AFlutter_SOA_MAT_SOAP_[OLD_VERSION] #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::09_Factor_Xa_Inhibitors_(Apixaban/Rivaroxaban/Edoxaban) #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#AMBOSS::TB06Zi #AK_Step2_v12::!Shelf::IM #AK_Step2_v12::#SketchyNeurology::07_Neurovascular::02_Ischemic_Stroke::01_Ischemic_Embolic_Stroke #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::15_Antiplatelets,_Anticoagulants,_and_Thrombolytics #PANCE::EOR::EM #AK_Step1_v12::#Textbooks::#Blumenfeld_Neuroanatomy::10_Cerebral_Hemispheres_and_Vascular_Supply #AK_Step2_v12::#Bootcamp::Medicine::01_Cardiology::02_Valvular_Disease::11_Complications_and_Critical_Interventions #AK_Step2_v12::#SketchyIM::02_ECG_Interpretation_&_Arrhythmias::04_Tachycardia::04_Narrow_Complex_Tachycardia:_AFib_&_AFlutter_Management #AK_Step2_v12::#SketchyNeurology::07_Neurovascular::04_Stroke_Management::01_Ischemic_Stroke_Treatment #AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#B&B::16_Neuro::03_Neurovascular_Disorders::06_Treatment_of_TIA/Stroke::Extra #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #AK_Step1_v12::#UWorld::Step::15390 #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::03_Heparin_(MOA,_Indications,_ADR,_CI) #AK_Step2_v12::#UWorld::Step::6881 #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::02_Warfarin_(MOA,_Indications,_AR,_CI) #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::04_Direct_coagulation_factor_inhibitors::*Direct_Factor_Xa_Inhibitors #AK_Step2_v12::#UWorld::COMLEX::101238 #PANCE::CARDIO::conduction_disorders/dysrhythmias #AK_Step1_v12::#UWorld::COMLEX::26286 #AK_Step1_v12::#Textbooks::#Golan_Pharmacology::23_Pharmacology_Of_Hemostasis_and_Thrombosis #AK_Step2_v12::#UWorld::Step::4452 #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::04_Direct_Acting_Oral_Anticoagulants_(DOACs)_(MOA,_Indications,_AR,_CI) #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #PANCE::EOR::Family_med #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants::Extra #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents #AK_Step1_v12::#Physeo::^physeo_image_update